《大行報告》野村下調翰森製藥(03692.HK)目標價至20.88元 評級「買入」
野村發表研究報告指,翰森製藥(03692.HK)去年收入及純利按年增長約14%及6%,當中收入高於野村預測,盈利則較市場及該行預期低。毛利率增長0.4個百分點至91.2%,主要是由於高利潤的新藥銷售增長,但有部分被仿製藥降價所抵銷。
該行維持「買入」評級,並輕微調整今明兩年的盈利預測,目標價從21.11元下調至20.88元,表示看好公司腫瘤新藥增長加快及公司以創新爲導向的轉型計劃,又指出去年腫瘤藥物收入增長令人鼓舞 ,看好核心產品阿莫替尼的增長前景,針對非小細胞肺癌的一線治療新適應症已於去年12月獲批,料將進一步增強公司競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.